Vitamin D3 for Life

Live Enlightened

Research libraryVitamin D3 For Life
Study design and methods

Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

Why this paper is included

Supporting source evidence:

Predictors of standardized bone marker concentrations; results of stepwise multiple linear regression analyses. | BAP SDS | TRAP SDS | Sclerostin SDS | cFGF-23 SDS | | ß ± SE | Part.R2 | p | ß ±SE | Part.R2 | p | ß ±SE | Part.R2 | p | ß ±SE | Part.R2 | p: Serum 25OHD (µg/l) | 0.23 ±0.12 | 0.07 | 0.05 | 0.16 ±0.09 | 0.006 | 0.09 | 0.22 ± 0.07 | 0.017 | 0.003 | | |

Source: Results table. View original paper

Relevance classification does not establish study quality, causation or editorial approval.

Study design Study design awaiting verification.

Study design awaiting verification

The available source does not establish a sufficiently clear study design.

Meta-analysis unclear · Blinding unclear / not reported · Human research reported

How this paper was classified

Automatic source-based classification; awaiting editorial verification. This is not a quality score.

Bone alkaline phosphatase (BAP), tartrate-resistant acid phosphatase 5b (TRAP5b), sclerostin and C-terminal FGF-23 (cFGF23) normalized for age and sex were analyzed in 556 children aged 6 to 18 years with an estimated glomerular filtration rate (eGFR) of 10 to 60 ml/min/1.73m2.

Source: Abstract.

View supporting evidence in the original paper

What the study types mean
Systematic review
Uses explicit methods to identify, assess and summarise research on a defined question.
Scoping review
Maps the extent and characteristics of research on a topic.
Narrative review
Discusses existing research; systematic-review methods have not been established by this classification.
Review / evidence synthesis
Reviews existing research; the exact review methods need further assessment.
Randomised controlled trial
Assigns participants or groups to comparison interventions by chance.
Non-randomised intervention study
Examines an intervention without random allocation.
Cohort study
Examines exposures and outcomes over time within a defined group.
Case-control study
Compares people with an outcome against people without it, examining exposures.
Cross-sectional study
Examines a population at a particular point in time.
Observational study
Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
Case report
Describes an individual case.
Case series
Describes a group of individual cases.
Secondary analysis
Analyses existing study data; this paper is not automatically another independent trial.
Laboratory study
Investigates biological processes in a laboratory setting.
Qualitative study
Examines experiences or meanings using qualitative methods.
Genetic instrumental-variable study
Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
Study protocol
Describes planned methods and is not evidence that the planned study has reported results.
Multiple reported designs
More than one design is explicitly reported; examine the supporting methods.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.

Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.

Abstracts

Markers of Bone Metabolism Are Affected by Renal Function and Growth Hormone Therapy in Children with Chronic Kidney Disease

Study design awaiting verification · PLoS ONE · 2015

Original publication title

Markers of Bone Metabolism Are Affected by Renal Function and Growth Hormone Therapy in Children with Chronic Kidney Disease

Anke Doyon; Dagmar-Christiane Fischer; Aysun Karabay Bayazit; Nur Canpolat; Ali Duzova; Betül Sözeri; Justine Bacchetta; Ayse Balat; Anja Büscher; Cengiz Candan; Nilgun Cakar; Osman Donmez; Jiri Dusek; Martina Heckel; Günter Klaus; Sevgi Mir; Gül Özcelik; Lale Sever; Rukshana Shroff; Enrico Vidal; Elke Wühl; Matthias Gondan; Anette Melk; Uwe Querfeld; Dieter Haffner; Franz Schaefer; for the 4C Study Consortium

© 2015 Doyon et al

Original publication · Publisher record · CC BY 4.0

Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.

Authors’ conclusion

Markers of bone metabolism indicate a high-bone turnover state in children with chronic kidney disease. Growth hormone induces an osteoanabolic pattern and normalizes osteocyte activity. The osteocyte markers cFGF23 and sclerostin are associated with standardized height, and the markers of bone turnover predict height velocity.

An extract from the source publication. Read it in context.

At a glance

Abstract: What objectives does the paper state?

The extent and relevance of altered bone metabolism for statural growth in children with chronic kidney disease is controversial. We analyzed the impact of renal dysfunction and recombinant growth hormone therapy on a panel of serum markers of bone metabolism in a large pediatric chronic kidney disease cohort.

Source: Objectives

Abstract: What methods does the paper describe?

Bone alkaline phosphatase (BAP), tartrate-resistant acid phosphatase 5b (TRAP5b), sclerostin and C-terminal FGF-23 (cFGF23) normalized for age and sex were analyzed in 556 children aged 6 to 18 years with an estimated glomerular filtration rate (eGFR) of 10 to 60 ml/min/1.73m2. 41 children receiving recombinant growth hormone therapy were compared to an untreated matched control group.

Source: Methods

Abstract: Results

Standardized levels of BAP, TRAP5b and cFGF-23 were increased whereas sclerostin was reduced. BAP was correlated positively and cFGF-23 inversely with eGFR. Intact serum parathormone was an independent positive predictor of BAP and TRAP5b and negatively associated with sclerostin. BAP and TRAP5B were negatively affected by increased C-reactive protein levels. In children receiving recombinant growth hormone, BAP was higher and TRAP5b lower than in untreated controls. Sclerostin levels were in the normal range and higher than in untreated controls. Serum sclerostin and cFGF-23 independently predicted height standard deviation score, and BAP and TRAP5b the prospective change in height standard deviation score.

Source: Results

Abstract: Conclusion

Markers of bone metabolism indicate a high-bone turnover state in children with chronic kidney disease. Growth hormone induces an osteoanabolic pattern and normalizes osteocyte activity. The osteocyte markers cFGF23 and sclerostin are associated with standardized height, and the markers of bone turnover predict height velocity.

Source: Conclusion
Authors’ abstract

Objectives

The extent and relevance of altered bone metabolism for statural growth in children with chronic kidney disease is controversial. We analyzed the impact of renal dysfunction and recombinant growth hormone therapy on a panel of serum markers of bone metabolism in a large pediatric chronic kidney disease cohort.

Methods

Bone alkaline phosphatase (BAP), tartrate-resistant acid phosphatase 5b (TRAP5b), sclerostin and C-terminal FGF-23 (cFGF23) normalized for age and sex were analyzed in 556 children aged 6 to 18 years with an estimated glomerular filtration rate (eGFR) of 10 to 60 ml/min/1.73m2. 41 children receiving recombinant growth hormone therapy were compared to an untreated matched control group.

Results

Standardized levels of BAP, TRAP5b and cFGF-23 were increased whereas sclerostin was reduced. BAP was correlated positively and cFGF-23 inversely with eGFR. Intact serum parathormone was an independent positive predictor of BAP and TRAP5b and negatively associated with sclerostin. BAP and TRAP5B were negatively affected by increased C-reactive protein levels. In children receiving recombinant growth hormone, BAP was higher and TRAP5b lower than in untreated controls. Sclerostin levels were in the normal range and higher than in untreated controls. Serum sclerostin and cFGF-23 independently predicted height standard deviation score, and BAP and TRAP5b the prospective change in height standard deviation score.

Conclusion

Markers of bone metabolism indicate a high-bone turnover state in children with chronic kidney disease. Growth hormone induces an osteoanabolic pattern and normalizes osteocyte activity. The osteocyte markers cFGF23 and sclerostin are associated with standardized height, and the markers of bone turnover predict height velocity.

Publication and source details

Original title: Markers of Bone Metabolism Are Affected by Renal Function and Growth Hormone Therapy in Children with Chronic Kidney Disease

Anke Doyon; Dagmar-Christiane Fischer; Aysun Karabay Bayazit; Nur Canpolat; Ali Duzova; Betül Sözeri; Justine Bacchetta; Ayse Balat; Anja Büscher; Cengiz Candan; Nilgun Cakar; Osman Donmez; Jiri Dusek; Martina Heckel; Günter Klaus; Sevgi Mir; Gül Özcelik; Lale Sever; Rukshana Shroff; Enrico Vidal; Elke Wühl; Matthias Gondan; Anette Melk; Uwe Querfeld; Dieter Haffner; Franz Schaefer; for the 4C Study Consortium

PLoS ONE · 2015

Competing Interests: We have the following interests. This study was partly funded by Pfizer Deutschland GmbH. There are no patents, products in development or marketed products to declare. This does not alter our adherence to all the PLOS ONE policies on sharing data and materials, as detailed online in the guide for authors.

Conceived and designed the experiments: AD DF DH FS. Performed the experiments: AD DF AKB NCan ADu BS JB ABa ABü CC NCak OD JD MH GK SM GÖ LS RS EV EW AM UQ. Analyzed the data: AD MG. Contributed reagents/materials/analysis tools: DF MG. Wrote the paper: AD DF DH FS.

‡ These authors contributed equally to this work.

¶ Membership of the 4C Study Consortium is listed in the Acknowledgments.

* E-mail: anke.doyon@med.uni-heidelberg.de
© 2015 Doyon et al2015Doyon et alhttps://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.This study has been made possible by grants of the KfH Foundation for Preventive Medicine, the European Renal Association: European Dialysis and Transplant Association (www.era-edta.org), the German Federal Ministry of Education and Research (reference number: 01EO0802) and Pfizer Deutschland GmbH. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Repository JATS snapshot; version as supplied

Source retrieved: 2026-11-12T20:34:02.322404+00:00

DOI: 10.1371/journal.pone.0113482 · PMC4319910